Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

732
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
732
Therapeutic Index01:13

Therapeutic Index

5.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
5.1K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.0K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.8K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

384
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
384

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.

Clinical toxicology (Philadelphia, Pa.)·2026
Same author

Greater than additive interactions between two phenolic pesticides used to control invasive sea lamprey (Petromyzon marinus): Underlying mechanisms and implications.

Aquatic toxicology (Amsterdam, Netherlands)·2026
Same author

National survey of Dutch emergency physicians on pharmacological sedation practices for extreme agitation.

Toxicology reports·2026
Same author

The first Dutch experience with a nurse-led outpatient clinic for the prevention and treatment of LARS after colorectal surgery: promising results of a standardized treatment protocol.

Techniques in coloproctology·2025
Same author

Differences in the clinical presentation of acute 3,4-methylenedioxymetamfetamine intoxication by co-intoxication and patient sex to European emergency departments.

Clinical toxicology (Philadelphia, Pa.)·2025
Same author

Application of European Society of Cardiology guidelines for evaluating acute coronary syndrome risk in low-risk patients with cocaine-associated chest pain: Findings from the RISK study - An observational analysis.

Toxicology reports·2024

Related Experiment Video

Updated: Sep 14, 2025

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

3.3K

Digoxin toxicity with therapeutic serum digoxin concentrations.

J Graafsma1,2, N Cimic3, M Dijkman4

  • 1Department of Hospital Pharmacy, Frisius MC, Heerenveen, the Netherlands.

Toxicology Reports
|July 21, 2025
PubMed
Summary

Digoxin toxicity can occur even at therapeutic serum concentrations. Clinical symptoms, not just levels, are crucial for diagnosis and guiding treatment with digoxin-specific antibody fragments.

Keywords:
Digoxin antibodiesDigoxin toxicityHyperkalemiaRenal failure

More Related Videos

Detection of Toxin Translocation into the Host Cytosol by Surface Plasmon Resonance
10:41

Detection of Toxin Translocation into the Host Cytosol by Surface Plasmon Resonance

Published on: January 3, 2012

13.4K
Preparation of Herbal Medicine: Er-Xian Decoction and Er-Xian-containing Serum for In Vivo and In Vitro Experiments
08:07

Preparation of Herbal Medicine: Er-Xian Decoction and Er-Xian-containing Serum for In Vivo and In Vitro Experiments

Published on: May 31, 2017

11.1K

Related Experiment Videos

Last Updated: Sep 14, 2025

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

3.3K
Detection of Toxin Translocation into the Host Cytosol by Surface Plasmon Resonance
10:41

Detection of Toxin Translocation into the Host Cytosol by Surface Plasmon Resonance

Published on: January 3, 2012

13.4K
Preparation of Herbal Medicine: Er-Xian Decoction and Er-Xian-containing Serum for In Vivo and In Vitro Experiments
08:07

Preparation of Herbal Medicine: Er-Xian Decoction and Er-Xian-containing Serum for In Vivo and In Vitro Experiments

Published on: May 31, 2017

11.1K

Area of Science:

  • Cardiology
  • Clinical Pharmacology

Background:

  • Digoxin is a vital cardiac glycoside for atrial fibrillation and heart failure.
  • Its narrow therapeutic window poses a risk of severe toxicity, including arrhythmias.
  • Current guidelines offer inconsistent advice on using serum digoxin concentrations for toxicity diagnosis and treatment decisions.

Observation:

  • A 76-year-old male presented with bradycardia, hyperkalemia, and acute kidney injury.
  • Despite therapeutic serum digoxin levels (1.4 ng/mL), symptoms indicated severe digoxin toxicity.
  • Standard treatments failed to resolve the patient's critical condition.

Findings:

  • Digoxin toxicity manifested clinically despite serum concentrations within the therapeutic range.
  • Digoxin-specific antibody fragments rapidly resolved hyperkalemia, bradycardia, and hemodynamic instability.
  • This case highlights that clinical presentation is paramount in diagnosing digoxin toxicity.

Implications:

  • Emphasizes the critical role of clinical assessment over solely relying on serum digoxin levels for toxicity diagnosis.
  • Supports the use of digoxin-specific antibody fragments for severe toxicity, irrespective of serum concentration.
  • Suggests a need for updated guidelines to incorporate clinical features more prominently in managing digoxin toxicity.